Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 369 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... July 22, 2022 Improving Care for Underserved People With Cancer and Evaluating Delays in... September 20, 2021 Detecting multiple cancers with a ‘simple’ blood test: Where are we? April 14, 2022 FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer... June 10, 2026 Load more HOT NEWS ESMO Advocates for Equal Access to Optimal Cancer Care for all... FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer
